

NEUROTREND

Neurological MRI-based biomarkers for treatment navigation in depression

Introduction and objective


Major depressive disorder (MDD) is a severe neuropsychiatric disorder with a global *lifetime prevalence of 15% to 18%*¹. Two-third of MDD patients remains symptomatic after first-line treatment and about one-third will not achieve remission after finishing four subsequent treatments^{1,2}. We aim to:

- Identify MRI-based biomarkers to improve treatment decision-making using longitudinal outcome of major depressive disorder
- Conduct psychiatric evaluation of depression and related comorbidity using questionnaires and history taking
- Evaluate cognition using eye-tracking methods and psychometric assessment




Psychiatric evaluation and cognitive assessments

- History taking including medication
- DSM-5 Diagnosis and Specifiers
- Hamilton Depression Rating Scale (17 items)
- Hamilton Anxiety Rating Scale (14 items)
- Cognitive Emotional Regulation Questionnaire




Study design



Inclusion criteria

- DSM-5 diagnosis of MDD
- Unipolar depression
- Age: 18-65 (m/f)




MRI Protocol*

Type of MRI sequence	Purpose
Survey	Localization and planning
T1-weighted (MPRAGE)	Anatomy
T2-weighted (FLAIR)	White matter lesions, anatomy
T2-weighted (TSE)	High-resolution subcortical anatomy
T2*-weighted (SWI/QSM)	Iron, microbleeds, large vessels, anatomy
Diffusion-weighted Imaging (DWI)	Anatomical connectivity
Resting-state fMRI (EPI)	Functional connectivity
Task-based fMRI (EPI)	Evoked brain activity
Microvascular MRI (IVIM)	Blood flow / micro vessels
Estimated total time: 59 minutes	

* Scanned with a Philips 3T Achieva scanner using compressed SENSE

Milestones



Contact information

Jesper Pilmeyer:
j.pilmeyer@tue.nl
TU/e, Flux 5.084

Faroeq Ramsaransing:
f.ramsaransing@gmail.com
GGzE